⚕ GalenOps field
←

SITE014-0082

completed

A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE014 (NLD) · Dr. Moreau
consented 2022-05-25

AEs
6
Serious
0
Dropout signal
–

Adverse events

moderate assessed

Grade 2 Anaemia — outcome: RECOVERED/RESOLVED; onset 2022-08-18 (study day 71); relationship: Y

mild assessed

Grade 1 Anaemia — outcome: RECOVERED/RESOLVED; onset 2022-10-13 (study day 127); relationship: N

mild assessed

Grade 1 Nausea — outcome: RECOVERED/RESOLVED; onset 2022-12-02 (study day 177); relationship: not assessed

moderate assessed

Grade 2 Nausea — outcome: RECOVERED/RESOLVED; onset 2023-05-19 (study day 345); relationship: not assessed

mild assessed

Grade 1 Alopecia — outcome: RECOVERED/RESOLVED; onset 2024-08-27 (study day 811); relationship: Y

mild assessed

Grade 1 Anaemia — outcome: RECOVERED/RESOLVED; onset 2025-01-07 (study day 944); relationship: not assessed

Data queries

No data queries.